INTENSITY THERAPEUTICS INC SEC Filings

Intensity Therapeutics amended its bylaws to change the quorum for stockholder meetings from a majority to at least one-third of the voting power, whether present in person, by remote communication, or represented by proxy. The Board adopted the amendment effective August 12, 2025 and filed the full text as Exhibit 3.1. Separately, Nasdaq notified the company that it was not in compliance with the $2,500,000 stockholders' equity requirement, the company raised approximately $6.6 million in July through an at-the-market offering, and its quarterly report for the period ended June 30, 2025 states it believes it meets the equity requirement. Nasdaq has determined the company currently complies but warned that failure to evidence compliance at the next periodic report could lead to delisting procedures.

On 7 Aug 2025, Intensity Therapeutics, Inc. (Nasdaq: INTS) filed a Form 8-K to report the release of its financial results for the three and six months ended 30 Jun 2025. The filing itself does not contain any revenue, EPS or cash-flow figures; instead, management refers investors to the detailed data contained in the accompanying press release (Exhibit 99.1). No other material corporate actions, transactions, or leadership changes were disclosed. Standard forward-looking-statement language and exhibit listings (including an Inline XBRL cover page) are provided, and the company continues to qualify as an emerging growth company.

Intensity Therapeutics (INTS) filed its Q2-25 10-Q showing sharply lower spending but continued losses. R&D expense fell 57% YoY to $1.5 M and G&A fell 23% to $1.2 M, trimming the quarterly net loss to $2.5 M (-$0.13/sh) from $5.0 M (-$0.36/sh) a year ago. For the six-month period, the net loss was $5.9 M (-$0.35/sh) versus $9.6 M in 1H-24.

Liquidity. Cash & equivalents were $2.2 M on 30 Jun 25, down $0.4 M from year-end. Subsequent ATM sales added $6.6 M, and combined April and June public offerings plus Q2 ATM activity brought in $4.1 M during the quarter. Management believes cash now extends into 2H-26, yet the filing still cites substantial doubt about going-concern status.

Clinical pipeline. • Phase 3 INVINCIBLE-3 (sarcoma) enrollment paused in March due to funding; 23 patients accrued, treatment continues. • Phase 2 INVINCIBLE-4 (TNBC) ongoing with target completion 1H-26 subject to financing. • Phase 1/2 IT-01 and Phase 2 INVINCIBLE-2 completed.

Capital structure. Share count rose to 26.2 M from 15.1 M at YE-24 through offerings and ESPP issuances; APIC stands at $74.8 M, while the accumulated deficit reached $72.7 M.

Nasdaq compliance. The company believes recent equity raises restored the minimum $2.5 M shareholders’ equity requirement but still faces $1.00 bid-price deficiency.

Intensity Therapeutics has filed an S-8 registration statement to register additional shares under its employee benefit plans. The registration covers:

• 529,300 additional shares of common stock under the 2021 Stock Incentive Plan (adding to 4,196,606 previously registered shares)
• 500,000 new shares under the 2024 Employee Stock Purchase Plan

The company is classified as a non-accelerated filer, smaller reporting company, and emerging growth company. The filing incorporates by reference several documents including the company's 2024 Annual Report, Q1 2025 Quarterly Report, and recent Current Reports. The registration includes standard indemnification provisions for directors and officers under Delaware law, backed by D&O insurance coverage.